CooperVision Completes Enrollment for Large-Scale Pediatric Myopia Control Study
Tuesday, May 19 2026 | 10 h 41 min | News
CooperVision has announced the completion of enrollment in its global MiSight® 1 day post-approval clinical studies in the United States and China, marking a milestone in the development of real-world evidence for pediatric myopia control.
According to the company, these studies, together with the seven-year clinical trial of ActivControl® Technology, make up the longest and most comprehensive clinical evidence program undertaken to date for contact lens-based myopia control in children. The program includes both randomized controlled efficacy trials and large-scale safety registries.
CooperVision said the combined post-approval study programs span more than 100 clinical sites and include over 3,000 children. The company noted that the resulting data will add to the existing body of research on MiSight® 1 day, which has already been widely published and cited in ophthalmology and optometry.
The announcement coincides with Myopia Awareness Week 2026, running from May 18 to 24, and aligns with the company’s broader focus on advancing understanding of pediatric myopia, a condition expected to affect nearly half the global population by 2050.
“Completing enrollment is a crucial step, allowing us to start analyzing data that will further illustrate how MiSight® 1 day performs in real-world settings over multiple years,” said Kathryn Richdale, OD, PhD, Director of Post-Market Clinical Affairs at CooperVision. “The findings will further strengthen the existing evidence supporting MiSight® 1 day, helping eye care professionals continue to make informed myopia management decisions and reinforcing long-term confidence for families.”
According to CooperVision, participants in the multi-year studies represent populations across both the U.S. and China, with final data expected to be released on a rolling basis between 2027 and 2030.
The company also announced the release of Progress in Focus: The Global Impact of MiSight® 1 day, a report that brings together evidence related to the MiSight product family and outlines its development, including the planned Canadian introduction of MyDay® MiSight® 1 day.
Click HERE for the press release.
Want to see more like this article? Click here to subscribe to our FREE print magazines and e-newsletters!
